Anika Therapeutics
ANIK
109 hedge funds and large institutions have $206M invested in Anika Therapeutics in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 39 reducing their positions, and 27 closing their positions.
52% more call options, than puts
Call options by funds: $47K | Put options by funds: $31K
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
2.94% less ownership
Funds ownership: 88.47% → 85.53% (-2.9%)
11% less funds holding
Funds holding: 122 → 109 (-13)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
36% less capital invested
Capital invested by funds: $324M → $206M (-$117M)
44% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFA
Alta Fundamental Advisers
New York
|
+$7.98M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.35M |
| 3 |
JP Morgan Chase
New York
|
+$1.32M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.21M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$965K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.2M |
| 2 |
BlackRock
New York
|
-$4.08M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$3.38M |
| 4 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$2.69M |
| 5 |
RP
Riverwater Partners
Milwaukee,
Wisconsin
|
-$2.55M |
ANIK Hedge Fund Activity: Q4 2024 in Review
109 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2024, worth a combined $206M — down 36% from $324M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ANIK and 15 opened new positions — a net loss of 12 holders — while 39 trimmed existing stakes and 39 added.
The largest buyer was Alta Fundamental Advisers, adding an estimated $7.98M. The largest seller was Morgan Stanley, cutting an estimated $5.2M.
- 109 institutional investors held Anika Therapeutics (ANIK) as of Q4 2024, down from 122 in Q3 2024.
- Funds reported $206M of Anika Therapeutics stock for Q4 2024, down 36% quarter-over-quarter.
- 15 funds opened new Anika Therapeutics positions in Q4 2024 and 27 closed out, a net change of -12 holders.
- The largest Anika Therapeutics buyer in Q4 2024 was Alta Fundamental Advisers, an estimated $7.98M added.
- The largest Anika Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $5.2M sold.
Based on aggregated 13F filings for Q4 2024.